Skip to main content
. 2012 Jul 4;103(9):1679–1687. doi: 10.1111/j.1349-7006.2012.02339.x

Fig. 1.

Fig. 1

Patient inclusion in the study. DCIS, ductal carcinoma in situ; DFS, disease-free survival; ER, estrogen receptor; ILC, invasive lobular carcinoma; MBC, metastatic breast cancer; MU, mucoid adenocarcinoma; PR, progesterone receptor; other rare types including phyllodes tumor, adenoid cystic carcinoma, neuroendocrine carcinoma, metaplastic carcinoma and lymphoma of breast cancer.